These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 16763467)

  • 1. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
    Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
    Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use.
    Matsumura T; Hayakawa M; Shimada F; Yabuki M; Dohanish S; Palkowitsch P; Yoshikawa K
    Magn Reson Med Sci; 2013 Dec; 12(4):297-304. PubMed ID: 24172794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
    Abujudeh HH; Kosaraju VK; Kaewlai R
    AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy.
    Goyen M; Debatin JF
    J Magn Reson Imaging; 2004 Mar; 19(3):261-73. PubMed ID: 14994293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event reporting in publications compared with sponsor database for cancer clinical trials.
    Scharf O; Colevas AD
    J Clin Oncol; 2006 Aug; 24(24):3933-8. PubMed ID: 16921045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
    Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
    Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
    Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
    Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylaxis to gadolinium radiocontrast: a case report and review of the literature.
    Shepherd M; Lata S; Mani S; Fiorillo A; Kumar P
    J La State Med Soc; 2009; 161(5):282-4. PubMed ID: 19927942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
    Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla.
    Bueltmann E; Erb G; Kirchin MA; Klose U; Naegele T
    Invest Radiol; 2008 Oct; 43(10):695-702. PubMed ID: 18791411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients.
    Kopp AF; Mortele KJ; Cho YD; Palkowitsch P; Bettmann MA; Claussen CD
    Acta Radiol; 2008 Oct; 49(8):902-11. PubMed ID: 18651252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.